预约演示
更新于：2026-02-01
Telbivudine
替比夫定
更新于：2026-02-01
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (2006-10-25), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C10H14N2O5 |
InChIKeyIQFYYKKMVGJFEH-CSMHCCOUSA-N |
CAS号3424-98-4 |
关联
80
项与 替比夫定 相关的临床试验ChiCTR2100048992
A prospective cohort study of potent and rapid inhibition of viral replication in the treatment of chronic hepatitis B
ChiCTR-OPN-17012206
Non-randomized, open clinical study of efficacy and safety of tenofovir combined with telbivudine in the treatment of HBeAg positive chronic hepatitis B patients
CTR20171290
替比夫定片在健康受试者中的单剂量、空腹/餐后、随机、开放、两周期、两交叉生物等效性研究
100 项与 替比夫定 相关的临床结果
登录后查看更多信息
100 项与 替比夫定 相关的转化医学
登录后查看更多信息
100 项与 替比夫定 相关的专利（医药）
登录后查看更多信息
1,083
项与 替比夫定 相关的文献（医药）2026-01-01AMERICAN JOURNAL OF SPORTS MEDICINE
Reversal of Pseudoparalysis in Posterosuperior Irreparable Rotator Cuff Tears: Superior Capsular Reconstruction vs Latissimus Dorsi Tendon Transfer vs Lower Trapezius Tendon Transfer
Article
作者: Baek, Chang Hee ; Jin Kim, Seung ; Lim, Chaemoon ; Taek Kim, Bo ; Gon Kim, Jung
Background::
Superior capsular reconstruction (SCR), latissimus dorsi tendon transfer (LDT), and lower trapezius tendon transfer (LTT) can be used to manage posterosuperior irreparable rotator cuff tears (PSIRTCs) with nonarthritic pseudoparalysis. However, no study has compared SCR, LDT, and LTT as joint-preserving treatment options for PSIRCTs with pseudoparalysis.
Purpose/Hypothesis::
This study aimed to compare the clinical and radiologic outcomes of SCR, LDT, and LTT in PSIRCTs with nonarthritic pseudoparalysis. It was hypothesized that LTT would be the most effective joint-preserving treatment option for PSIRCTs with pseudoparalysis.
Study Design::
Retrospective case-control study; Level of evidence, 3.
Methods::
A retrospective review was conducted of 59 patients with PSIRCTs who had nonarthritic pseudoparalysis and underwent surgical treatment between January 2014 and December 2020. The cohorts consisted of 19 patients who underwent SCR, 16 patients who underwent LDT, and 20 patients who underwent LTT. Pseudoparalysis was defined as forward elevation (FE) remaining <90° after pain was alleviated with a lidocaine injection. Because the best joint-preserving technique is defined by the reversal of pseudoparalysis, the primary outcome was the reversal rate of pseudoparalysis. Secondary clinical outcomes were assessed by visual analog scale score, patient-reported outcome measurements (PROMs), active range of motion (aROM), and muscle strength. Radiologic outcomes were evaluated by the progression of osteoarthritic change and graft integrity. All clinical and radiologic outcomes were compared between the preoperative evaluation and the 4-year postoperative evaluation.
Results::
In postoperative PROMs and aROM including abduction (ABD) and external rotation (ER), and muscle strength of FE, ABD, and ER, a statistically significant difference was found between the 3 groups, and the LTT group showed the most favorable outcomes among the 3 groups. Although postoperative mean FE did not show a significant difference among the 3 groups, the reversal rate of pseudoparalysis of the LTT group (90.0%) was significantly highest among the 3 groups (SCR group 52.6%; LDT group 68.7%;
P
= .014), indicating that LTT was the most effective method to reverse pseudoparalysis. The LDT group showed the highest rate of progression of osteoarthritic change, and the SCR group showed the highest rate of graft retear.
Conclusion::
Although SCR, LDT, and LTT all demonstrated significant improvements in clinical outcomes for patients with PSIRCTs and nonarthritic pseudoparalysis, LTT tended to show the most favorable results in terms of PROM, aROM, muscle strength, and reversal rate of pseudoparalysis. This may be attributed to the biomechanical advantages of LTT in restoring force coupling and counterbalancing the deltoid muscle. Therefore, LTT could be considered a preferred treatment option for PSIRCTs with nonarthritic pseudoparalysis.
2026-01-01JOURNAL OF MEDICAL VIROLOGY
Dynamics of Serum Hepatitis B Virus Nucleic Acids in Patients With Chronic Hepatitis B After Stopping Nucleos(t)ide Analogs Reveal Delayed Rebound of Hepatitis B Virus RNA
Article
作者: Shen, Sheng ; Liang, Wanying ; Chen, Yidan ; Liang, Hongyan ; Zeng, Ge ; Liu, Shi ; Hou, Jinlin ; Sun, Jian ; Liang, Xieer ; Lu, Xingyu ; Deng, Rui ; Fan, Rong ; Li, Wanying
ABSTRACT:
Serum HBV RNA, an emerging biomarker, was reported to require a longer duration than HBV DNA to achieve undetectable levels during nucleos(t)ide analogs (NAs) therapy according to the analysis of viral nucleic acid kinetics. However, detailed information about the viral dynamics of off‐treatment remains unclear. A total of 32 hepatitis B e antigen (HBeAg)–positive patients who stopped telbivudine‐based therapy after meeting stopping criteria were included. Laboratory assays were tested every 12 or 16 weeks. The extracellular and intracellular viral dynamics in HepAD38 cells were monitored during and after NA exposure. NA therapy induced a significantly faster decline of serum HBV DNA than serum HBV RNA (slope, −0.1103 vs. −0.0459,
p
< 0.0001). After treatment cessation, serum HBV DNA rebounded more rapidly than serum HBV RNA during virological relapse (slope, 0.1752 vs. 0.1142,
p
= 0.0184). The peak rebound amplitude of serum HBV DNA occurred within the first 12 weeks off‐treatment, significantly surpassing that of serum HBV RNA [0.24 (0.12, 0.46) vs. 0 (0, 0.10),
p
< 0.0001]. During the off‐treatment phase in HepAD38 cells, different from the strong rebound of extracellular HBV DNA (56.40‐fold,
p
< 0.0001) with faster rebound kinetics (slope, 0.1479 vs. 0.0249,
p
< 0.0001), extracellular HBV RNA increased only 2.65‐fold (
p
= 0.0452). This occurred despite a significantly faster rebound of intracellular HBV RNA compared to HBV DNA (0.0106 vs. 0.2508,
p
< 0.0001). In conclusion, serum HBV RNA rebounded later and less prominently than serum HBV DNA after NAs cessation. The HepAD38 model indicated preferential intracellular HBV RNA utilization for HBV DNA synthesis and secretion upon reverse transcription reactivation.
2026-01-01Indian Journal of Orthopaedics
Comparative Effectiveness of Iontophoresis vs. Low Dye Taping in Plantar Fasciitis: A Systematic Review
Review
作者: Tovaruela-Carrión, Natalia ; Castro-Méndez, Aurora ; Roldán-Fernández, Lucía ; Pabón-Carrasco, Manuel ; Álvarez-Cordero, Juan ; Vázquez-Castro, María
Abstract:
Background:
Plantar fasciitis (PF) is a frequent cause of heel pain, affecting approximately 10% of the population. Conservative treatments such as iontophoresis and low-dye taping (LDT) are widely used to alleviate symptoms, often providing short-term pain relief.
Objective:
This systematic review aims to compare the efficacy of iontophoresis (with 5% acetic acid, 0.4% dexamethasone, dexamethasone and lidocaine, or placebo) versus low-dye taping (LDT) in treating plantar fasciitis. Additionally, it evaluates the combined effect of iontophoresis and LDT application.
Methods:
A systematic search was conducted in Scopus, PubMed, Web of Science, CINAHL, and the Cochrane Library databases, following PRISMA guidelines and the Cochrane Handbook for Systematic Reviews of Interventions. Inclusion and exclusion criteria were predefined. Two independent reviewers screened and extracted data from eligible studies, assessing their quality. Included studies comprised randomized controlled trials, non-randomized clinical trials, case–control studies, systematic reviews, and meta-analyses. The review protocol was registered with PROSPERO (registration number: [blind for review]).
Results:
Eight studies published between 1997 and 2018 were included, providing a moderate level of evidence. Both iontophoresis (with the specified agents) and low-dye taping, alone or combined, were associated with statistically significant reductions in pain scores compared to baseline.
Conclusion:
Iontophoresis and low-dye taping are effective conservative interventions for plantar fasciitis, with their combined use also showing beneficial effects. These treatments can be considered viable options to reduce pain in patients with plantar fasciitis.
35
项与 替比夫定 相关的新闻（医药）2026-01-30
2026-01-30
100 项与 替比夫定 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 乙型肝炎 | 中国 | 2008-01-20 | |
| 慢性乙型肝炎 | 美国 | 2006-10-25 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 完全性房室传导阻滞 | 临床3期 | 美国 | 2006-12-01 | |
| 纤维化 | 临床3期 | 美国 | 2003-12-01 | |
| 纤维化 | 临床3期 | 中国 | 2003-12-01 | |
| 纤维化 | 临床3期 | 澳大利亚 | 2003-12-01 | |
| 纤维化 | 临床3期 | 加拿大 | 2003-12-01 | |
| 纤维化 | 临床3期 | 法国 | 2003-12-01 | |
| 纤维化 | 临床3期 | 德国 | 2003-12-01 | |
| 纤维化 | 临床3期 | 印度 | 2003-12-01 | |
| 纤维化 | 临床3期 | 以色列 | 2003-12-01 | |
| 纤维化 | 临床3期 | 拉脱维亚 | 2003-12-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 108 | Telbivudine (LdT) | 網鬱鹹簾膚觸選淵壓鬱(鹽觸遞糧艱鏇範願鑰鑰) = 齋廠願願艱積膚夢範網 顧選積齋齋艱觸鹹顧衊 (獵齋顧淵膚衊憲醖簾餘 ) 更多 | - | 2020-12-07 | ||
临床3期 | 53 | (Telbivudine) | 艱鹽網簾遞顧鬱糧鏇壓 = 簾顧憲醖選願積觸淵製 範鏇衊築壓構憲夢廠繭 (願衊簾鬱繭膚觸製壓蓋, 獵鏇網醖鑰觸製顧醖獵 ~ 鹹築齋窪餘艱鑰糧製願) 更多 | - | 2019-09-10 | ||
Placebo (Placebo) | 艱鹽網簾遞顧鬱糧鏇壓 = 鏇鏇鹹簾憲築鬱夢襯憲 範鏇衊築壓構憲夢廠繭 (願衊簾鬱繭膚觸製壓蓋, 願鏇網壓願鏇醖鏇製獵 ~ 壓繭廠衊壓範築鹹齋築) 更多 | ||||||
临床4期 | 241 | 繭製鹹襯簾鑰夢製選鏇 = 顧鏇顧襯憲艱鏇顧餘鑰 齋築憲淵遞築鹽醖網襯 (夢製艱襯憲夢艱鏇壓鏇, 鏇築衊鹽願蓋獵憲選願 ~ 鏇觸夢餘鬱壓鑰窪襯齋) 更多 | - | 2018-11-05 | |||
(TDF Overall) | 繭製鹹襯簾鑰夢製選鏇 = 鹹網鏇繭顧壓網艱淵衊 齋築憲淵遞築鹽醖網襯 (夢製艱襯憲夢艱鏇壓鏇, 鏇齋窪構範糧築憲憲蓋 ~ 窪構範襯鏇窪積齋壓醖) 更多 | ||||||
临床4期 | 328 | 獵遞窪觸鬱憲積築繭繭(構夢衊衊築糧範觸窪襯) = 憲築鏇鹽夢憲鹹範鑰製 獵製窪廠憲願製願選顧 (獵廠鑰鬱鑰鑰遞鹽網醖 ) | - | 2018-04-01 | |||
(Control (no antiviral agent)) | 製鑰網糧積廠膚衊網選(襯範鹹遞構廠鑰齋繭鹹) = 齋選夢衊醖艱窪鏇鹹築 獵觸醖憲憲獵糧憲築製 (選顧選糧衊繭夢淵繭遞 ) 更多 | ||||||
N/A | 397 | Group A | 艱艱醖鑰夢鏇顧範築醖(鹽鬱鹹齋構廠餘衊築願) = 鏇衊憲餘艱積艱簾襯鬱 鬱鑰淵餘範選襯構構蓋 (壓餘窪鬱製觸選繭壓鹹 ) | - | 2017-11-01 | ||
Group B | 艱艱醖鑰夢鏇顧範築醖(鹽鬱鹹齋構廠餘衊築願) = 鏇鹽築憲繭醖齋顧襯淵 鬱鑰淵餘範選襯構構蓋 (壓餘窪鬱製觸選繭壓鹹 ) 更多 | ||||||
临床4期 | - | 214 | 鬱窪構襯廠餘蓋積選艱(膚鹽繭積艱鹽積簾築網) = 餘簾觸壓簾夢觸鑰糧願 衊顧鬱蓋艱遞廠積遞糧 (衊夢鬱淵憲鹹醖夢繭製 ) 更多 | - | 2017-06-01 | ||
临床3期 | 97 | 範構繭選鹹鹽襯艱築製(鹽襯膚餘憲築淵選廠膚) = 繭壓網觸鹽夢顧選鏇憲 構鏇鏇廠淵網齋鑰壓範 (衊鹹夢廠醖顧衊鏇夢淵 ) 更多 | 不佳 | 2017-01-19 | |||
範構繭選鹹鹽襯艱築製(鹽襯膚餘憲築淵選廠膚) = 餘選夢鹽夢齋鬱願鑰顧 構鏇鏇廠淵網齋鑰壓範 (衊鹹夢廠醖顧衊鏇夢淵 ) 更多 | |||||||
临床2/3期 | 120 | Lamivudine-continuous | 顧醖願壓壓齋顧範願膚(夢製壓鏇積憲鬱窪鏇齋) = Eleven (18.3%) patients with telbivudine developed polyneuritis during the trial and post hoc following-up 膚餘醖製襯構鬱膚餘獵 (壓醖襯鹽夢網繭顧膚夢 ) | - | 2017-01-01 | ||
Telbivudine-replacement | |||||||
临床4期 | 57 | 觸膚鬱積築膚簾繭衊壓(鑰製範遞襯襯衊齋繭膚) = 築觸壓製醖窪顧繭鬱簾 餘積範齋蓋衊鏇蓋艱構 (願積繭鹹觸遞範糧繭構 ) 更多 | - | 2015-08-01 | |||
Lamivudine 100 mg/day + Telbivudine | 觸膚鬱積築膚簾繭衊壓(鑰製範遞襯襯衊齋繭膚) = 構簾淵艱積襯簾醖齋淵 餘積範齋蓋衊鏇蓋艱構 (願積繭鹹觸遞範糧繭構 ) | ||||||
临床3期 | 159 | Telbivudine plus PegIFN alpha-2a | 積築鹽醖膚範積壓廠顧(廠鏇襯衊選築鹹積衊夢) = Peripheral neuropathy occurred in 7/50, 1/54, and 0/54 patients in the three groups of safety populations, respectively 鹹鏇夢夢齋齋獵鏇憲鹹 (觸廠繭積觸醖廠襯築餘 ) | 不佳 | 2015-01-01 | ||
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用